|Central Nervous System||Pre-Clinical & Clinical||Co-Lead||Member|
NeurAxon is a leader in discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. Since its inception in 2004, NeurAxon has been dedicated to developing novel pain therapeutics targeting neuronal nitric oxide synthase (nNOS). The Company has issued and pending composition of matter patents on selective small molecule inhibitors of nNOS. The focus of the Company’s efforts is to continue to build upon this intellectual property asset and leverage it with product focused medicinal chemistry, biology and clinical development expertise to create a pipeline of proprietary single and dual-action small molecule nNOS inhibitors for migraine and other pain indications. NeurAxon’s research operations are located in Toronto, Ontario.
480 University Avenue
Toronto, ON. M5G 1V2
Telephone: (416) 673-6697
Fax: (416) 595-8249